AUS
NZ
UK
CA
USA
IND
Health
Immuron Ltd Records Strong Sales Growth for Travelan in Latest Quarter
October 15, 2024 06:45 PM AEDT| By Team Kalkine MediaHighlights,Travelan sales grew by 13% in the September quarter.,Australia saw a 3% rise in Travelan sales.,North American sales surged by 48%, showing significant market expansion.,Immuron Ltd (ASX:IMC) has reported solid sales growth for its immune...
Share Consolidations and Clinical Advancements in ASX Companies
October 15, 2024 04:14 PM AEDT| By Team Kalkine MediaHighlights,Invion and Wellnex Life implement share consolidations.,Invion begins trial for non-melanoma skin cancer, while Wellnex migrates to the London Stock Exchange.,Artrya progresses toward US FDA approval for its cardiovascular AI device.,Share...
Lumos Diagnostics Holdings (ASX:LDX) Shows Impressive Surge, But Challenges Remain
October 14, 2024 03:24 PM AEDT| By Team Kalkine MediaHighlights,Lumos Diagnostics Holdings surged 35% despite lagging industry trends.,The company's revenue has declined over the past three years,,impacting,its valuation.,Market sentiment,remains,cautious due to lower growth expectations.,Lumos Diagnos...
LTR Pharma Nasal Solution SPONTAN A Game Changer in Faster Absorption
October 14, 2024 11:54 AM AEDT| By Team Kalkine MediaHighlights,LTR Pharma’s nasal spray shows a 470% faster absorption rate.,The product boasts higher bioavailability compared to oral tablets.,No adverse effects were reported in clinical trials.,LTR Pharma,(ASX:LTP),has revealed promising final study...
Vitura Health's (ASX:VIT) Balance Sheet Overview
October 14, 2024 11:10 AM AEDT| By Team Kalkine MediaHighlights,Vitura,Health carries low debt and solid cash reserves,.,The company's liabilities exceed cash and receivables but remain manageable,.,Vitura,Health generates strong free cash flow, supporting debt management,.,Vitura Health Limited,(ASX:V...
Amplia Therapeutics Recognized with Prime Minister’s Prize for Innovation
October 10, 2024 07:58 PM AEDT| By Team Kalkine MediaHighlights,Amplia,Therapeutics team,awarded,the 2024 Prime Minister’s Prize for Innovation.,Their co-invention,,momelotinib,, is now approved for treating myelofibrosis.,Amplia,Therapeutics is advancing promising cancer treatments, including,narmafot...
Innovative Tech Boosts Control Bionics' Growth Prospects
October 10, 2024 07:50 PM AEDT| By Team Kalkine MediaHighlights:,Control Bionics targets 20% revenue growth and near-term EBITDA positivity.,Sigma Healthcare led healthcare sector gains with a 186% rise over the year.,Noxopharm secures manufacturing for its autoimmune diseases trial.,Control Bionics (A...
Imagion Biosystems Raises $3 Million for Cancer Diagnostics Advancements
October 10, 2024 07:00 PM AEDT| By Team Kalkine MediaHighlights,Imagion Biosystems secures $3 million through a capital raise.,Funds to advance the MagSense platform, targeting cancer diagnosis improvements.,Positive results from Phase 1 breast cancer study for MagSense technology.,Imagion Biosystems (...
Recce Pharmaceuticals Advances Testing of Skin Infection Gel
October 09, 2024 06:06 PM AEDT| By Team Kalkine MediaHighlights,Recce Pharmaceuticals progresses its Phase II trial for a topical gel.,Early data shows the gel is safe and demonstrates positive antibacterial effects.,Recruitment for the trial is on track to finish by the end of the year.,Recce Pharmace...
Orthocell Gains Regulatory Approval for Nerve Repair Product in Singapore
October 08, 2024 03:38 PM AEDT| By Team Kalkine MediaHighlights,Orthocell receives Singapore regulatory approval for Remplir.,Expansion plans include ASEAN markets and upcoming US FDA approval.,Record quarterly revenue of $2.03 million reported.,West Australian-based regenerative medicine company Ortho...
Orthocell Secures Singapore Regulatory Approval for Nerve Repair Product, Remplir™
October 08, 2024 01:40 PM AEDT| By Team Kalkine MediaKey Points:,Orthocell has secured regulatory approval in Singapore for its nerve repair product, Remplir, marking the first major international clearance outside of Australia and New Zealand.,The company is in advanced discussions with an internation...
Audeara Secures Major $570,000 Purchase Order from Clinico, Shares Surge 10.4%
October 08, 2024 01:23 PM AEDT| By Team Kalkine MediaKey Points:,Clinico, Taiwan’s largest hearing aid retailer, has placed a $570,000 purchase order with Audeara for healthy hearing earbuds.,The earbuds will be marketed and distributed across Taiwan and China, with an official launch expected in Q2 FY...
Orthocell Secures Key Approval in Singapore for Nerve Repair Product Remplir™
October 08, 2024 12:17 PM AEDT| By Team Kalkine MediaHighlights,Orthocell,receives regulatory approval in Singapore for its,Remplir,™ product.,Singapore acts as a gateway to other ASEAN markets for,Orthocell,.,Remplir,™ targets a global market opportunity exceeding US,$3.5 billion,.,Orthocell Ltd (ASX:...
Lumos Diagnostics Raises A$10 Million for Growth and Expansion
October 08, 2024 11:11 AM AEDT| By Team Kalkine MediaHighlights,Lumos Diagnostics completed a successful fundraising round.,The company raised a total of A$10 million through an entitlement offer.,Funds will be used for growth initiatives, including a key U.S. regulatory milestone.,Lumos Diagnostics Ho...
Pro Medicus (ASX:PME) Secures AU$98M, 8-Year Contract Renewal with Mercy Health
October 07, 2024 04:27 PM AEDT| By Team Kalkine MediaKey Points:,Pro Medicus' U.S. subsidiary signs an eight-year contract renewal with Mercy Health, valued at A$98 million.,The deal includes Visage 7 Viewer and Visage 7 Open Archive, with a higher per-transaction fee compared to the original contract....
Orthocell (ASX:OCC) Records Strong Growth in 2024
October 07, 2024 03:10 PM AEDT| By Team Kalkine MediaHighlights,Orthocell,achieved record revenue of A$2.03 million in Q3 2024.,Demand for key products Striate+ and,Remplir,continues to drive growth.,US FDA approval for,Remplir,could unlock a,$1.6 billion,nerve repair market.,Orthocell Ltd (ASX:OCC), a...
Mesoblast (ASX:MSB) Poised for Breakthrough as FDA Decision Nears
October 07, 2024 01:32 PM AEDT| By Team Kalkine MediaHighlights,Mesoblast shares have risen by 65% in the past month.,FDA approval for its stem-cell therapy,Ryoncil,is expected soon.,Mesoblast is advancing six programs in phase III clinical trials.,Mesoblast Limited (ASX:MSB), a leader in stem-cell the...
Cochlear Limited (ASX:COH) Sees Revised Valuation Amid Market Shifts
October 07, 2024 01:25 PM AEDT| By Team Kalkine MediaHighlights:,Cochlear's,stock declined over 13% after the August results, leading to a,reevaluation,.,Citi analysts have revised the price target for Cochlear from $255 to $305, citing a valuation,adjustment.,**,Cochlear's,price-earnings ratio for fis...
Chimeric Therapeutics (ASX:CHM) Reports Cancer Treatment Breakthrough
October 07, 2024 12:58 PM AEDT| By Team Kalkine MediaHighlights,Chimeric Therapeutics reports a complete response in a,leukaemia,patient during its latest drug trial.,The combination of ‘CORE-NK’ and,Vactosertib,shows potential in treating advanced cancer.,The ongoing trial aims to,enrol,12 patients, w...
Neuren Pharmaceuticals (ASX:NEU) Advances FDA-Approved Phase 3 Trial
October 07, 2024 12:39 PM AEDT| By Team Kalkine MediaHighlights,Neuren,Pharmaceuticals received positive FDA feedback for its Phase 3 trial.,The trial will focus on children with Phelan-McDermid Syndrome (PMS), testing NNZ-2591.,Neuren,is preparing trial sites and service providers for the next phase.,...
Advertise your brand on Kalkine Media